## Sanofi India Limited (SANOFI) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Sanofi India Limited (SANOFI) is a pharmaceutical company listed on the National Stock Exchange of India (NSE) since May 19, 2003.  It operates within the Pharmaceuticals & Biotechnology sector, specifically focusing on the Indian market.  The company's exact market positioning within the sector requires further research beyond the provided data, but its presence on the NSE suggests a significant market share within India.

**2. Market Data Analysis:**

| Metric                     | Value       | Notes                                                              |
|-----------------------------|-------------|----------------------------------------------------------------------|
| Current Price               | ₹6,210.00   |  Increased by ₹99.75 (1.63%) from the previous close.             |
| Percentage Change (PChange) | 1.63%       | Positive daily price movement.                                      |
| Pre-Open Activity          | ₹6,077.00   | Lower than the previous day's close, indicating potential downward pressure at the open.  Limited volume. |
| Week High                   | ₹10,524.95  | Significantly higher than the current price, suggesting recent volatility. |
| Week Low                    | ₹5,892.80   | Significantly lower than the current price, further highlighting volatility. |
| VWAP                        | ₹6,147.76   |  Close to the current price, suggesting relatively balanced trading. |
| Sector PE                   | 30.84       |  SANOFI's PE ratio (33.14) is slightly higher than the sector average. |
| Symbol PE                   | 33.14       | Higher than the sector average, potentially indicating higher valuation expectations. |
| Delivery Percentage         | 65.60%      |  A relatively high delivery percentage suggests a significant portion of trades were not speculative. |
| Market Depth                | Limited Data | The provided order book data shows zero buy and sell quantities, which is unusual and may indicate incomplete or delayed data. Further investigation is needed. |


**3. Financial Performance:**

The provided financial data shows a consistent profit after tax (PAT) and earnings per share (EPS) over the past five quarters. However, it's crucial to note that all figures are unaudited.  A detailed analysis requires audited financial statements.

| Quarter      | Revenue (₹) | Expenses (₹) | PAT (₹)     | EPS (₹)   |
|--------------|-------------|-------------|-------------|-----------|
| Q3 FY2024    | 52,630      | 41,371      | 8,219       | 35.69     |
| Q2 FY2024    | 46,830      | 35,720      | 10,340      | 44.90     |
| Q1 FY2024    | 73,890      | 52,380      | 13,660      | 59.31     |
| Q4 FY2023    | 70,590      | 51,710      | 13,770      | 59.79     |
| Q3 FY2023    | 72,640.16   | 51,633.3    | 15,213.59   | 66.08     |

**Key Financial Ratios:**  Further analysis is needed to calculate key ratios (e.g., Return on Equity, Debt-to-Equity) using audited financial statements.  The provided data only allows for a preliminary assessment.

**4. Corporate Actions and Announcements:**

Sanofi India has a history of significant dividend payouts, including interim and final dividends, and special dividends.  A recent demerger (ex-date June 13, 2024) is a notable event that requires further investigation to understand its impact on the stock price.  Several announcements related to share certificates and financial results are also present.

**5. Shareholding Patterns:**

The promoter holding has remained consistently at 60.40% over the past five quarters.  Public shareholding remains at 39.60%.  No significant shifts are observed.

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023  | 60.40                        | 39.60      | 0.00                           | 100.00    |
| 31-Dec-2023  | 60.40                        | 39.60      | 0.00                           | 100.00    |
| 31-Mar-2024  | 60.40                        | 39.60      | 0.00                           | 100.00    |
| 30-Jun-2024  | 60.40                        | 39.60      | 0.00                           | 100.00    |
| 30-Sep-2024  | 60.40                        | 39.60      | 0.00                           | 100.00    |


**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the wide gap between the week's high and low.  The CM Annual Volatility of 20.06% further confirms this.  The risk-reward profile is currently high risk due to the volatility and the need for further investigation into the demerger and incomplete market depth data.

**7. Advantages of Buying the Stock:**

* Consistent (unaudited) profitability and EPS growth over the past five quarters.
* High promoter holding, indicating strong management control.
* History of substantial dividend payouts.

**8. Disadvantages and Risks:**

* High volatility, potentially leading to significant price swings.
* Unclear impact of the recent demerger on future performance.
* Incomplete market depth data hinders a complete risk assessment.
* Reliance on unaudited financial data for analysis.


**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Hold.** The current price is near the VWAP, but the pre-open activity and high volatility suggest caution.  Further clarification on the market depth and the demerger's impact is needed before considering a buy.

* **Medium-Term (3 to 12 months): Hold.**  The consistent (unaudited) financial performance is positive, but the volatility remains a concern.  Monitoring the impact of the demerger and obtaining audited financial statements are crucial before making a buy decision.

* **Long-Term (1 year and beyond):  Don't Buy (for now).** While the company shows potential based on its consistent profitability and high promoter holding, the high volatility and lack of complete data make it too risky for a long-term investment at this time.  Further investigation is required.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 7/10 (Based on unaudited, positive EPS and PAT trends; requires audited data for a more accurate score)
* Market Performance: 6/10 (Positive PChange, but high volatility and incomplete market depth data are concerning)
* Volatility and Risk: 4/10 (High volatility is a significant risk)
* Corporate Actions and Governance: 8/10 (Consistent dividend payouts and high promoter holding are positive)
* Shareholding Patterns: 7/10 (Stable shareholding pattern)

**Analysis Score (out of 10): 7/10**

* Completeness and utilization of data: 6/10 (Some data is missing or incomplete, particularly market depth)
* Accuracy and clarity of analysis: 8/10 (Analysis is clear and well-structured, but limited by incomplete data)
* Professional formatting: 9/10 (Report is well-formatted and easy to read)


**11. Professional Recommendation Summary:**

Based on the available (but incomplete) data, Sanofi India shows some positive signs, particularly in its consistent profitability and high promoter holding. However, the high volatility and the lack of complete information regarding market depth and the recent demerger create significant uncertainty.  Therefore, a "Hold" recommendation is given for the short and medium term, while a "Don't Buy" is recommended for the long term until further investigation clarifies the outstanding issues.  Obtaining audited financial statements and a thorough analysis of the demerger's impact are crucial before any buy recommendation can be made.
